Hologic and Biotheranostics to Present New Data at 2025 SABCS on Breast Cancer Index Test's Expanded Utility in Personalizing Endocrine Therapy Duration

Hologic and Biotheranostics will present 11 studies at the 2025 San Antonio Breast Cancer Symposium. The studies support the Breast Cancer Index Test's established position as the only guideline-recognized and most extensively validated test to predict patients likely to benefit from extended endocrine therapy. New findings explore the test's potential expanded utility in premenopausal women and comparison to the 21-gene assay. The BCI Test identifies premenopausal patients with early-stage, HR+ breast cancer at minimal risk of distant recurrence.